Skip to main content
. 2022 Aug 23;37(1):2265–2282. doi: 10.1080/14756366.2022.2104841

Figure 12.

Figure 12.

2D diagram for the binding interactions of sorafenib in the VEGFR-2 active site (PDB: 4ASD).